Global Myelodysplastic Syndrome Therapeutics Market 2018-2022
出 版 商：Technavio
出版日期：2018/07/10
頁 數：119頁
文件格式：PDF
價 格：
USD 2,500 (Single-User License)
USD 3,000 (Multi-User License)
USD 4,000 (Global-User License)
USD 3,000 (Multi-User License)
USD 4,000 (Global-User License)
About Myelodysplastic Syndrome Therapeutics
Myelodysplastic syndrome (MDS) includes a group of clonal myeloid neoplasms characterized by cytopenia due to ineffective hematopoiesis, abnormal blood and marrow cell morphology, and a risk of clonal evolution and progression to AML.
Technavio’s analysts forecast the global myelodysplastic syndrome therapeutics market to grow at a CAGR of 2.54% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global myelodysplastic syndrome therapeutics market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of patented and generic drugs used to treat MDS.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Myelodysplastic Syndrome Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ Celgene
‧ Otsuka
‧ Novartis
Market driver
‧ Improved prognostic classification of MDS through advanced technologies
‧ For a full, detailed list, view our report
Market challenge
‧ Inadequacies in treatment landscape of MDS
‧ For a full, detailed list, view our report
Market trend
‧ High incidence in older adult population
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2022 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Myelodysplastic syndrome (MDS) includes a group of clonal myeloid neoplasms characterized by cytopenia due to ineffective hematopoiesis, abnormal blood and marrow cell morphology, and a risk of clonal evolution and progression to AML.
Technavio’s analysts forecast the global myelodysplastic syndrome therapeutics market to grow at a CAGR of 2.54% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global myelodysplastic syndrome therapeutics market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of patented and generic drugs used to treat MDS.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Myelodysplastic Syndrome Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ Celgene
‧ Otsuka
‧ Novartis
Market driver
‧ Improved prognostic classification of MDS through advanced technologies
‧ For a full, detailed list, view our report
Market challenge
‧ Inadequacies in treatment landscape of MDS
‧ For a full, detailed list, view our report
Market trend
‧ High incidence in older adult population
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2022 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
‧ Market ecosystem
‧ Market characteristics
‧ Market segmentation analysis
PART 05: PIPELINE ANALYSIS
‧ MDS Pipeline
PART 06: MARKET SIZING
‧ Market definition
‧ Market sizing 2017
‧ Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
‧ Bargaining power of buyers
‧ Bargaining power of suppliers
‧ Threat of new entrants
‧ Threat of substitutes
‧ Threat of rivalry
‧ Market condition
PART 08: MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION
‧ Segmentation by ROA
‧ Comparison by ROA
‧ Oral drugs – Market size and forecast 2017-2022
‧ Parenteral Drugs – Market size and forecast 2017-2022
‧ Market opportunity by route of administration
PART 09: MARKET SEGMENTATION BY SUB-TYPE OF MDS
‧ Segmentation by sub-type of MDS
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
‧ Geographical segmentation
‧ Regional comparison
‧ Americas – Market size and forecast 2017-2022
‧ EMEA – Market size and forecast 2017-2022
‧ APAC – Market size and forecast 2017-2022
‧ Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
‧ Market drivers
‧ Market challenges
PART 14: MARKET TRENDS
‧ High cost of disease-management
‧ High incidence in older adult population
PART 15: VENDOR LANDSCAPE
‧ Overview
‧ Landscape disruption
PART 16: VENDOR ANALYSIS
‧ Vendors covered
‧ Market positioning of vendors
‧ Celgene
‧ Otsuka
‧ Novartis
PART 17: APPENDIX
‧ List of abbreviations
Exhibit 01: Global oncology market
Exhibit 02: Parent market: The global oncology market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Drugs approved by US FDA for MDS
Exhibit 06: Drugs approved by European Medicines Agency (EMA) for MDS
Exhibit 07: MDS pipeline phase II development stage agents
Exhibit 08: MDS pipeline phase III development stage agents
Exhibit 09: Treatment Algorithm in MDS
Exhibit 10: Market definition - Inclusions and exclusions checklist
Exhibit 11: Market size 2017
Exhibit 12: Validation techniques employed for market sizing 2017
Exhibit 13: Global MDS therapeutics market – Market size and forecast 2017-2022 ($ bn)
Exhibit 14: Global MDS therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 15: Five forces analysis 2017
Exhibit 16: Five forces analysis 2022
Exhibit 17: Bargaining power of buyers
Exhibit 18: Bargaining power of suppliers
Exhibit 19: Threat of new entrants
Exhibit 20: Threat of substitutes
Exhibit 21: Threat of rivalry
Exhibit 22: Market condition - Five forces 2017
Exhibit 23: Global MDS therapeutics market by ROA – Market share 2017-2022 (%)
Exhibit 24: Comparison by ROA
Exhibit 25: Oral drugs – Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Oral drugs – Year-over-year growth 2018-2022 (%)
Exhibit 27: Parenteral drugs – Market size and forecast 2017-2022 ($ bn)
Exhibit 28: Parenteral drugs – Year-over-year growth 2018-2022 (%)
Exhibit 29: Market opportunity by route of administration
Exhibit 30: Customer landscape
Exhibit 31: Global MDS therapeutics market by geography – Market share 2017-2022 (%)
Exhibit 32: Regional comparison
Exhibit 33: Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 34: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in Americas
Exhibit 36: EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 37: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in EMEA
Exhibit 39: APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 40: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 41: Top 3 countries in APAC
Exhibit 42: Market opportunity
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Market positioning of vendors
Exhibit 47: Vendor classification
Exhibit 48: Celgene overview
Exhibit 49: Celgene– Business segments
Exhibit 50: Celgene – Organizational developments
Exhibit 51: Celgene – Geographic focus
Exhibit 52: Celgene – Segment focus
Exhibit 53: Celgene – Key Offerings
Exhibit 54: Otsuka overview
Exhibit 55: Otsuka - Business segments
Exhibit 56: Otsuka – Organizational developments
Exhibit 57: Otsuka – Geographic focus
Exhibit 58: Otsuka – Segment focus
Exhibit 59: Otsuka– Key offerings
Exhibit 60: Novartis overview
Exhibit 61: Novartis – Business segments
Exhibit 62: Novartis – Organizational developments
Exhibit 63: Novartis – Geographic focus
Exhibit 64: Novartis – Segment focus
Exhibit 65: Novartis – Key offerings
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
‧ Market ecosystem
‧ Market characteristics
‧ Market segmentation analysis
PART 05: PIPELINE ANALYSIS
‧ MDS Pipeline
PART 06: MARKET SIZING
‧ Market definition
‧ Market sizing 2017
‧ Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
‧ Bargaining power of buyers
‧ Bargaining power of suppliers
‧ Threat of new entrants
‧ Threat of substitutes
‧ Threat of rivalry
‧ Market condition
PART 08: MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION
‧ Segmentation by ROA
‧ Comparison by ROA
‧ Oral drugs – Market size and forecast 2017-2022
‧ Parenteral Drugs – Market size and forecast 2017-2022
‧ Market opportunity by route of administration
PART 09: MARKET SEGMENTATION BY SUB-TYPE OF MDS
‧ Segmentation by sub-type of MDS
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
‧ Geographical segmentation
‧ Regional comparison
‧ Americas – Market size and forecast 2017-2022
‧ EMEA – Market size and forecast 2017-2022
‧ APAC – Market size and forecast 2017-2022
‧ Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
‧ Market drivers
‧ Market challenges
PART 14: MARKET TRENDS
‧ High cost of disease-management
‧ High incidence in older adult population
PART 15: VENDOR LANDSCAPE
‧ Overview
‧ Landscape disruption
PART 16: VENDOR ANALYSIS
‧ Vendors covered
‧ Market positioning of vendors
‧ Celgene
‧ Otsuka
‧ Novartis
PART 17: APPENDIX
‧ List of abbreviations
Exhibit 01: Global oncology market
Exhibit 02: Parent market: The global oncology market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Drugs approved by US FDA for MDS
Exhibit 06: Drugs approved by European Medicines Agency (EMA) for MDS
Exhibit 07: MDS pipeline phase II development stage agents
Exhibit 08: MDS pipeline phase III development stage agents
Exhibit 09: Treatment Algorithm in MDS
Exhibit 10: Market definition - Inclusions and exclusions checklist
Exhibit 11: Market size 2017
Exhibit 12: Validation techniques employed for market sizing 2017
Exhibit 13: Global MDS therapeutics market – Market size and forecast 2017-2022 ($ bn)
Exhibit 14: Global MDS therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 15: Five forces analysis 2017
Exhibit 16: Five forces analysis 2022
Exhibit 17: Bargaining power of buyers
Exhibit 18: Bargaining power of suppliers
Exhibit 19: Threat of new entrants
Exhibit 20: Threat of substitutes
Exhibit 21: Threat of rivalry
Exhibit 22: Market condition - Five forces 2017
Exhibit 23: Global MDS therapeutics market by ROA – Market share 2017-2022 (%)
Exhibit 24: Comparison by ROA
Exhibit 25: Oral drugs – Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Oral drugs – Year-over-year growth 2018-2022 (%)
Exhibit 27: Parenteral drugs – Market size and forecast 2017-2022 ($ bn)
Exhibit 28: Parenteral drugs – Year-over-year growth 2018-2022 (%)
Exhibit 29: Market opportunity by route of administration
Exhibit 30: Customer landscape
Exhibit 31: Global MDS therapeutics market by geography – Market share 2017-2022 (%)
Exhibit 32: Regional comparison
Exhibit 33: Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 34: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in Americas
Exhibit 36: EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 37: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in EMEA
Exhibit 39: APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 40: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 41: Top 3 countries in APAC
Exhibit 42: Market opportunity
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Market positioning of vendors
Exhibit 47: Vendor classification
Exhibit 48: Celgene overview
Exhibit 49: Celgene– Business segments
Exhibit 50: Celgene – Organizational developments
Exhibit 51: Celgene – Geographic focus
Exhibit 52: Celgene – Segment focus
Exhibit 53: Celgene – Key Offerings
Exhibit 54: Otsuka overview
Exhibit 55: Otsuka - Business segments
Exhibit 56: Otsuka – Organizational developments
Exhibit 57: Otsuka – Geographic focus
Exhibit 58: Otsuka – Segment focus
Exhibit 59: Otsuka– Key offerings
Exhibit 60: Novartis overview
Exhibit 61: Novartis – Business segments
Exhibit 62: Novartis – Organizational developments
Exhibit 63: Novartis – Geographic focus
Exhibit 64: Novartis – Segment focus
Exhibit 65: Novartis – Key offerings
